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The prevention of rickets and osteoporosis by vitamin D has long been established. More recently, vitamin D has been implicated in many metabolic and immunological disorders as well as many cancers. Its pleiotropic activity may be mediated by modulation of \~1000 genes via the vitamin D receptor (VDR),[1](#bjd17992-bib-0001){ref-type="ref"}, [2](#bjd17992-bib-0002){ref-type="ref"} which is expressed by at least 60 human cell types.[3](#bjd17992-bib-0003){ref-type="ref"} The VDR controls many cellular functions including growth, differentiation and apoptosis. However, the role of vitamin D in the prevention of nonskeletal diseases remains highly controversial.[4](#bjd17992-bib-0004){ref-type="ref"}, [5](#bjd17992-bib-0005){ref-type="ref"}, [6](#bjd17992-bib-0006){ref-type="ref"}, [7](#bjd17992-bib-0007){ref-type="ref"}, [8](#bjd17992-bib-0008){ref-type="ref"}

Terrestrial ultraviolet radiation (UVR) is the main determinant of vitamin D status. Stratospheric ozone absorbs all solar UVC (100--280 nm), attenuates UVB (280--315 nm) but not UVA (315--400 nm). The sun\'s height determines the UVR pathlength through the ozone layer. Thus, UVB intensity (irradiance) depends mainly on latitude, season and time of day. The ratio of UVA to UVB also varies with the sun\'s height because of the differential effect of the ozone layer. Thus, terrestrial UVR typically contains ≤ 5% UVB (\~295--315 nm) and ≥ 95% UVA.

The minor UVB component is responsible for vitamin D synthesis,[9](#bjd17992-bib-0009){ref-type="ref"} the initiating event of which is the isomerization of the epidermal chromophore (a UVR‐absorbing molecule) 7‐dehydrocholesterol (7‐DHC) into pre‐vitamin D~3~, which is thermally converted into cholecalciferol (vitamin D~3~).[10](#bjd17992-bib-0010){ref-type="ref"} Pre‐vitamin D~3~ increases linearly as a function of time of exposure to UVR (i.e. dose) over a period of 30 min.[11](#bjd17992-bib-0011){ref-type="ref"} Vitamin D~3~ enters the circulation via the vitamin D binding protein (DBP) and is hydroxylated into 25‐hydroxyvitamin D~3~ \[25(OH)D~3~\] in the liver \[by vitamin D~3~‐25‐hydroxylase (CYP2R1)\], and then in the kidney \[by 25(OH)D~3~‐1α‐hydroxylase (CYP27B1)\] to 1,25‐dihydroxyvitamin D~3~ \[1,25(OH)~2~D~3~\], the active form of vitamin D (calcitriol), which in fact is a hormone. However, many tissues including the skin[12](#bjd17992-bib-0012){ref-type="ref"} also contain both hydroxylases for the synthesis of calcitriol.

Multiple intrinsic and extrinsic factors modulate vitamin D synthesis and overall status, including genetic polymorphisms, age, geographical location, sun exposure behaviour, UVB dose, clothing, body surface area (BSA) exposed.[13](#bjd17992-bib-0013){ref-type="ref"} These are summarized in Figure [1](#bjd17992-fig-0001){ref-type="fig"}, [14](#bjd17992-bib-0014){ref-type="ref"} and Appendix [S1](#bjd17992-sup-0001){ref-type="supplementary-material"} (see Supporting Information). Vitamin D~3~ may also be obtained from supplementation and/or animal‐based foods (e.g. oily fish) and undergoes the same hydroxylations. Alternatively, vitamin D~2~ from nonanimal dietary uptake (e.g. mushrooms), is hydroxylated into 25(OH)D~2~ and then converted into 1,25(OH)~2~D~2~ (ergocalciferol). However, in general, intake from diet is low. For example, food intake in the U.S.A. between 2005 and 2006 in 19--30‐year‐old males and females was 204 IU ± 12 (5·1 μg) and 144 IU ± 12 (3·6 μg), respectively, which represents 34% and 24% of the recommended dietary allowance (RDA).[15](#bjd17992-bib-0015){ref-type="ref"}

![Factors that affect the synthesis of vitamin D~3~. Many factors determine vitamin D~3~ production. The most important external factor is UVB dose, which is the product of UVB intensity (irradiance) and exposure time. Cutaneous pre‐vitamin D~3~ is synthesized from 7‐dehydrocholesterol after UVB exposure. Thermally converted into vitamin D~3~, it then binds to vitamin D binding protein (DBP) in the blood to be activated sequentially by the liver and kidney. Cytochrome P450 (CYP) enzymes are crucial for the synthesis of biologically active vitamin D~3~ (calcitriol), which binds to intracellular vitamin D receptor (VDR) in most cells in the body. Adapted from Jolliffe *et al*.[14](#bjd17992-bib-0014){ref-type="ref"} More details of these factors are given in the Supporting Information. BSA, body surface area; RXR, retinoid X receptor; VDRE, vitamin D response element.](BJD-181-916-g001){#bjd17992-fig-0001}

Solar UVR has many adverse effects, the most obvious of which is sunburn (erythema). The World Health Organization has defined the global solar UV index (UVI) (<http://www.who.int/uv/publications/en/UVIGuide.pdf>) to allow comparisons of erythemal potential at various geographical locations (latitudes), seasons and times of day.[16](#bjd17992-bib-0016){ref-type="ref"} This is a numerical index of the erythemally weighted irradiance of terrestrial UVR. It is divided into five bands: 'low' (1--2), 'moderate' (3--5), 'high' (6--7), 'very high' (8--10) and 'extreme' (≥ 11). The UVI is primarily an index of UVB irradiance because this spectral region is the main cause of erythema (see Conclusions and recommendations: Spectral considerations: Ultraviolet B, below) and sun protection is advised when the UVI is ≥ 3.[17](#bjd17992-bib-0017){ref-type="ref"}

Global concern about vitamin D deficiency has fuelled debates on the importance of solar exposure to meet vitamin D requirements.[18](#bjd17992-bib-0018){ref-type="ref"}, [19](#bjd17992-bib-0019){ref-type="ref"}, [20](#bjd17992-bib-0020){ref-type="ref"}, [21](#bjd17992-bib-0021){ref-type="ref"} The acute and chronic health benefits of using sunscreens are established[22](#bjd17992-bib-0022){ref-type="ref"} but there has been concern about their possible impact on vitamin D status. An international panel was tasked to review the published evidence to reach a consensus on the influence of photoprotection by sunscreens on vitamin D status, considering other relevant factors.

Methods {#bjd17992-sec-0007}
=======

The panel comprised experts from diverse disciplines including vitamin D, endocrinology, dermatology, photoprotection, experimental photobiology, epidemiology and anthropology. Panel members made a comprehensive search of literature published from January 1996 to May 2017, using the Scopus database, with the following search term categories individually and in combination: *vitamin D*,*status*,*level*,*values*,*deficiency*,*measurement*,*assay*,*dosage*,*evaluation*,*polymorphisms*,*genetics*,*diet*,*phototype*,*pigmentation*,*lifestyle*,*location*,*latitude*,*sun*,*UV*,*UVR*,*ultraviolet*,*health*,*diseases*,*sunscreen*,*photoprotection* or *sun protection*. Members of the panel used their specific areas of expertise to identify relevant papers and presented and discussed their results at a meeting in Paris in June 2017. The panel discussion was recorded by a scientific writer and used as the basis of the manuscript. Additional 2017--19 references were included during the writing process. This article summarizes the consensus and provides clinical recommendations in terms of photoprotection in order to ensure optimal vitamin D status.

Conclusions and recommendations from panel discussions {#bjd17992-sec-0008}
======================================================

What is optimal vitamin D status and the best method to determine it? {#bjd17992-sec-0009}
---------------------------------------------------------------------

Serum 25(OH)D is the best indicator of vitamin D status but there is no international consensus on its optimal value, with recommendations varying from 25 nmol L^−1^ to \> 100 nmol L^−1^.[23](#bjd17992-bib-0023){ref-type="ref"} Figure [2](#bjd17992-fig-0002){ref-type="fig"} summarizes the definitions of vitamin D status by various international bodies.[23](#bjd17992-bib-0023){ref-type="ref"} The most widely held consensus for the boundary between insufficiency and sufficiency is 50 nmol L^−1^. According to the Institute of Medicine (IOM),[15](#bjd17992-bib-0015){ref-type="ref"} a serum concentration of 50 nmol L^−1^ 25(OH)D meets or exceeds the requirement of 97·5% of the U.S. population, but it is not possible to specify desired individual status.[23](#bjd17992-bib-0023){ref-type="ref"} The determination of vitamin D status is discussed in Appendix [S2](#bjd17992-sup-0001){ref-type="supplementary-material"} (see Supporting Information).

![Thresholds of serum 25(OH)D concentration recommended by different bodies for definitions of vitamin D status (adapted from Bouillon[23](#bjd17992-bib-0023){ref-type="ref"}). Red, deficiency; orange, insufficiency; green, sufficiency. AAP, American Academy of Pediatrics; AGS, American Geriatrics Society; DACH, Deutschland, Austria and Confederation Helvetica; GRIO, French Research and Information Group on Osteoporosis; IOF, International Osteoporosis Foundation; IOP, Institute of Medicine; SACN, Scientific Advisory Committee on Nutrition (U.K.).](BJD-181-916-g002){#bjd17992-fig-0002}

Public health perspectives {#bjd17992-sec-0010}
--------------------------

Hypovitaminosis D is prevalent globally.[22](#bjd17992-bib-0022){ref-type="ref"}, [24](#bjd17992-bib-0024){ref-type="ref"}, [25](#bjd17992-bib-0025){ref-type="ref"} A systematic review covering 168 000 people from 44 countries reported serum 25(OH)D \< 50 nmol L^−1^ in 37% of studies.[26](#bjd17992-bib-0026){ref-type="ref"} This was mainly in the Middle East[27](#bjd17992-bib-0027){ref-type="ref"} and Asia despite high insolation, emphasizing the importance of human behaviour.

Medical conditions and treatments with high risk of vitamin D deficiency are summarized in Table [S1](#bjd17992-sup-0001){ref-type="supplementary-material"} (see Supporting Information). Concern about vitamin D status has resulted in increased screening with financial consequences.[28](#bjd17992-bib-0028){ref-type="ref"} Clinical practice guidelines from the Endocrine Society advise screening only for those at risk of deficiency.[29](#bjd17992-bib-0029){ref-type="ref"} In France, the Research and Information Group on Osteoporosis (GRIO) recommends systematic vitamin D supplementation without screening in everyone over 65 years.[30](#bjd17992-bib-0030){ref-type="ref"}

Disagreement on recommended doses for vitamin D supplementation arises, in part, from discrepancies of opinion on optimal serum 25(OH)D levels. The doses recommended for supplementation are discussed in Appendix [S2](#bjd17992-sup-0001){ref-type="supplementary-material"} (see Supporting Information), but in case of deficiency, vitamin D supplementation should be 600--800 IU (15--20 μg) daily \[but 400 IU (10 μg) in those less than 1‐year‐old\] to achieve at least a target serum level of 50 nmol L^−1^.

Sunscreens and sun protection indices {#bjd17992-sec-0011}
-------------------------------------

Sunscreens are topical formulations that contain chemicals that attenuate solar UVR.[31](#bjd17992-bib-0031){ref-type="ref"}, [32](#bjd17992-bib-0032){ref-type="ref"} Global regulatory authorities have defined the sun protection factor (SPF) of a sunscreen as a universal quantitative index of protection against erythema, assessed after a single exposure of solar‐simulated radiation (SSR; Fig. [3](#bjd17992-fig-0003){ref-type="fig"}a). In effect, the SPF is the ratio of SSR dose necessary for a minimal erythema dose (MED) with and without sunscreen application. SPF should be the primary driver of sunscreen choice. These authorities also require UVA protection (see Spectral considerations: Ultraviolet A). A given sunscreen, applied according to prescribed SPF test conditions at 2 mg cm^−2^, transmits 1⁄SPF of the erythemally effective UVR. One MED is equivalent to about three standard erythema doses (1 SED = 100 J m^−2^ of erythemally weighted UVR[33](#bjd17992-bib-0033){ref-type="ref"}) in a fair‐skinned person.[34](#bjd17992-bib-0034){ref-type="ref"} Thus, assuming a possible ambient exposure of 30 SED during a sunbathing session, the correct use of SPF 20 sunscreen will allow a suberythemal 1·5 SED to reach the skin. However, people typically apply very much less with a commensurate reduction of actual labelled SPF. For example, a study of Danes on holiday in Egypt reported a mean application thickness of 0·79 mg cm^−2^.[35](#bjd17992-bib-0035){ref-type="ref"} This paradoxically means that sunscreen use may be associated with sunburn as a result of more time in the sun.[36](#bjd17992-bib-0036){ref-type="ref"}, [37](#bjd17992-bib-0037){ref-type="ref"} Additional protection factors have been proposed, such as immune protection factor, DNA protection factor[31](#bjd17992-bib-0031){ref-type="ref"} and a protection factor for visible light.[38](#bjd17992-bib-0038){ref-type="ref"}

![Ultraviolet radiation (UVR) spectra and their interactions with action spectra. (a) UVR emission spectra of natural temperate noon summer sunlight (London, U.K.; 51·5° N), solar simulated radiation (SSR) from a Solar^®^ Light 16S‐001 v4·0 (Solar^®^ Light, Glenside, PA, U.S.A.) with an emission spectrum compliant for sun‐protection factor (SPF) testing with the International Organization for Standardization (ISO) Standard 24444 and Cosmetics Europe 2006 and a UVB phototherapy source (Philips TL20W/12 fluorescent tubes in combination with and without a UVC blocking filter (Kodacel) that has been widely used in vitamin D studies. Spectra are normalized at 315 nm (CIE boundary between UVB and UVA). (b) CIE action spectra for erythema[57](#bjd17992-bib-0057){ref-type="ref"} and formation of pre‐vitamin D~3~.[58](#bjd17992-bib-0058){ref-type="ref"} (c) UVR emission spectra weighed for erythema and pre‐vitamin D~3~ using the emission spectra in Figure [3](#bjd17992-fig-0003){ref-type="fig"}a and action spectra in Figure [3](#bjd17992-fig-0003){ref-type="fig"}b. These products give biologically effective energy and are normalized at 315 nm (CIE boundary between UVB and UVA). Comparisons of the UVB source, with and without Kodacel, weighted with the pre‐vitamin D action spectrum show the large influence of nonsolar UVR in many laboratory studies. Comparisons of the London solar spectrum weighted with the erythema and pre‐vitamin D action spectra show that UVA filters have no influence on vitamin D production.](BJD-181-916-g003){#bjd17992-fig-0003}

### The benefits of sunscreens in photoprotection strategies {#bjd17992-sec-0012}

The acute and chronic adverse effects of solar UVR, especially to those with fair skins, are well established and can be inhibited by effective sun protection.[22](#bjd17992-bib-0022){ref-type="ref"}, [25](#bjd17992-bib-0025){ref-type="ref"}, [39](#bjd17992-bib-0039){ref-type="ref"}, [40](#bjd17992-bib-0040){ref-type="ref"} This includes (i) sun avoidance or seeking shade; (ii) clothing; and (iii) sunscreen use. When used optimally sunscreens can prevent erythema during a week‐long holiday, even when the UVI is very high.[41](#bjd17992-bib-0041){ref-type="ref"} Laboratory studies have shown than sunscreens can prevent UVR‐induced immunosuppression[42](#bjd17992-bib-0042){ref-type="ref"} and the formation of DNA damage[43](#bjd17992-bib-0043){ref-type="ref"}, [44](#bjd17992-bib-0044){ref-type="ref"} \[specifically cyclobutane pyrimidine dimers (CPD), the action spectrum of which is very similar to erythema\].[45](#bjd17992-bib-0045){ref-type="ref"} CPD are thought to be important in many skin cancers. Those with cancer‐prone fair skin are especially sensitive to CPD formation, whereas the higher melanin content in dark skin affords much better protection against CPD, especially in the basal layer.[46](#bjd17992-bib-0046){ref-type="ref"}, [47](#bjd17992-bib-0047){ref-type="ref"}, [48](#bjd17992-bib-0048){ref-type="ref"}, [49](#bjd17992-bib-0049){ref-type="ref"}, [50](#bjd17992-bib-0050){ref-type="ref"} A recent study with a high SPF sunscreen and high‐dose SSR for 5 consecutive days showed significant protection against CPD, even when the sunscreen was applied at 0·75 mg cm^−2^ to simulate typical use.[44](#bjd17992-bib-0044){ref-type="ref"} A large Norwegian cohort showed that sunscreen use reduced the risk of melanoma.[51](#bjd17992-bib-0051){ref-type="ref"} Extensive randomized controlled trials in Australia, with long‐term follow‐up, have demonstrated the protective properties of a sunscreen against photoageing, melanoma and squamous cell carcinoma, but not basal cell carcinoma.[52](#bjd17992-bib-0052){ref-type="ref"}, [53](#bjd17992-bib-0053){ref-type="ref"}, [54](#bjd17992-bib-0054){ref-type="ref"}, [55](#bjd17992-bib-0055){ref-type="ref"}, [56](#bjd17992-bib-0056){ref-type="ref"}

### Spectral considerations {#bjd17992-sec-0013}

#### Ultraviolet B {#bjd17992-sec-0014}

Action spectroscopy shows that UVB is orders of magnitude more effective than UVA for erythema (see Fig. [3](#bjd17992-fig-0003){ref-type="fig"}b[57](#bjd17992-bib-0057){ref-type="ref"}, [58](#bjd17992-bib-0058){ref-type="ref"}).[45](#bjd17992-bib-0045){ref-type="ref"} This means that the SPF is primarily, but not exclusively, a measure of UVB protection.[31](#bjd17992-bib-0031){ref-type="ref"} Such protection is essential when UVB doses are high with recreational solar exposure, and in countries with high UVI.

#### Ultraviolet A {#bjd17992-sec-0015}

There has been an increasing trend over recent years for better UVA protection, with the aim of designing the ideal 'neutral density' sunscreen with 'spectral homeostasis' that mimics shade, i.e. it does not distort the natural solar UVR spectrum.[59](#bjd17992-bib-0059){ref-type="ref"} There is no global standard for UVA protection and requirements vary with regulatory domain.[31](#bjd17992-bib-0031){ref-type="ref"} The U.S. Food and Drug Administration has recently proposed greater UVA protection.[60](#bjd17992-bib-0060){ref-type="ref"} A UVA protection factor (UVA‐PF) can be obtained using a sunscreen\'s ability to inhibit persistent pigment darkening *in vivo*.[61](#bjd17992-bib-0061){ref-type="ref"} Spectral approaches, based on UVB/UVA absorption ratios and bandwidth cover, give qualitative but not quantitative information on UVA protection.

UVA irradiance is at least 20‐fold greater than UVB in sunlight.[62](#bjd17992-bib-0062){ref-type="ref"} Furthermore, because UVA is not attenuated by the ozone layer, it is much less prone than UVB to daily, seasonal and geographical variation. Efficient UVA protection is highly recommended in recreational and daily photoprotection strategies, because good UVB protection, which inhibits sunburn, enables prolonged solar exposure and the accumulation of unnaturally high UVA doses. UVA1 (340--400 nm) preferentially induces CPD in the basal layer, which contains stem cells and melanocytes,[63](#bjd17992-bib-0063){ref-type="ref"} as well as damaging DNA repair enzymes.[64](#bjd17992-bib-0064){ref-type="ref"} Increasing UVA protection for a given SPF results in a *de facto* reduction of UVB protection, which might be expected to be beneficial for vitamin D synthesis.

Studies *in vivo* or in 3D skin models, have shown that for a given SPF a high UVA‐PF sunscreen offers better protection against pigmentation, photoageing and DNA damage compared with low UVA‐PF, and that low SPF sunscreens with high UVA‐PF offer such protection (Table [1](#bjd17992-tbl-0001){ref-type="table"}).[65](#bjd17992-bib-0065){ref-type="ref"}, [66](#bjd17992-bib-0066){ref-type="ref"}, [67](#bjd17992-bib-0067){ref-type="ref"}, [68](#bjd17992-bib-0068){ref-type="ref"}, [69](#bjd17992-bib-0069){ref-type="ref"}, [70](#bjd17992-bib-0070){ref-type="ref"} One study, on a reconstructed skin model exposed to daily SSR, showed that a sunscreen with a lower SPF but strong UVA protection was more effective in preventing photodamage compared with a sunscreen with a higher SPF but low UVA protection.[66](#bjd17992-bib-0066){ref-type="ref"} Thus, overall there seems to be biological and clinical advantages from increasing UVA protection for a given SPF.

###### 

Daily photoprotection studies with solar type UVR sources and emphasis on impact of ultraviolet (UV) A protection; summary of main conclusions from laboratory photoprotection studies

  First author, year                                        Study model                                                         Exposure                                                                                         Sunscreen[a](#bjd17992-note-0004){ref-type="fn"} ^,^ [b](#bjd17992-note-0005){ref-type="fn"}   Conclusion
  --------------------------------------------------------- ------------------------------------------------------------------- ------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------
  Young 2007[65](#bjd17992-bib-0065){ref-type="ref"}        Healthy volunteers FST I/II                                         Daily suberythemal SSR exposure (11 days)                                                        Broad‐spectrum SS: SPF 7·5 UVA 4\*                                                             Prevention of DNA damage, p53 accumulation and Langerhans cell depletion
  Lejeune 2008[66](#bjd17992-bib-0066){ref-type="ref"}      3D human skin models                                                DUVR[c](#bjd17992-note-0006){ref-type="fn"} dose--response (0--90 J cm^−2^)                      SS with SPF 15 but high and low UVA‐PF with SPF/UVA‐PF ratio ≤ 3 or \> 3                       High UVA‐PF (SPF/UVA‐PF ratio ≤ 3) showed better prevention of dermal alterations
  Seité 2010[67](#bjd17992-bib-0067){ref-type="ref"}        Healthy volunteers FST II/III                                       Daily suberythemal DUVR[c](#bjd17992-note-0006){ref-type="fn"} exposure (19 days over 4 weeks)   Broad‐spectrum SS: SPF 8 UVA‐PF 7 UVA 3\*                                                      Prevention of p53‐positive cells, melanin increase, loss of HLA‐DR‐positive cells and induction of dermal modifications (GAG)
  Fourtanier 2012[68](#bjd17992-bib-0068){ref-type="ref"}   Asian (FST III) volunteers[d](#bjd17992-note-0007){ref-type="fn"}   DUVR[c](#bjd17992-note-0006){ref-type="fn"}                                                      SS with SPF 19, 30 and 50, each with high and low UVA‐PF                                       Better inhibition of pigmentation (at 7 days) with high UVA‐PF (SPF/UVA‐PF ratio ≤ 3)
  Marionnet 2012[70](#bjd17992-bib-0070){ref-type="ref"}    3D human skin models                                                DUVR[c](#bjd17992-note-0006){ref-type="fn"} exposure. 12 J cm^−2^                                SS with SPF 13 and high UVA‐PF (SPF/UVA‐PF ratio ≤ 3)                                          Inhibition of gene expression for adverse effects of DUVR

DUVR, daylight UVR; FST, Fitzpatrick skin type; GAG, glycosaminoglycans; HLA‐DR, human leukocyte antigen -- DR isotype; SPF, sun protection factor; SS, sunscreen; SSR, solar simulating radiation, UVA‐PF, UVA protection factor; UVR, ultraviolet radiation

SPF/UVA‐PF ratios from L\'Oréal: ≤ 3, well‐balanced UVB--UVA protection (according to EC requirements); \> 3, unbalanced SS with low UVA protection.

UVA star (\*) rating refers to a sunscreen\'s UVA : UVB absorbance ratio (Boots star rating method). The higher the rating, the better the UVA protection with a maximal value of 5 (which represents a more or less neutral density sunscreen).

DUVR has a UVA/UVB ratio of \~ 27 (96·5% UVA, 3·5% UVB), which is more typical of temperate sunlight compared with SSR used for SPF testing.

The FST type is not given in Fourtanier *et al*.,[68](#bjd17992-bib-0068){ref-type="ref"} but those authors refer to a poster by Moyal,[69](#bjd17992-bib-0069){ref-type="ref"} which gives further details.

John Wiley & Sons, Ltd

Does photoprotection by sunscreens have an influence on vitamin D status? {#bjd17992-sec-0016}
-------------------------------------------------------------------------

### Sunscreen use and vitamin D status {#bjd17992-sec-0017}

Given that solar UVB is the main source of vitamin D,[71](#bjd17992-bib-0071){ref-type="ref"}, [72](#bjd17992-bib-0072){ref-type="ref"} a possible adverse effect of sunscreen use on vitamin D synthesis has important public health implications. This has been studied using the different approaches described below. Reviews on sunscreen use and vitamin D synthesis have concluded that sunscreen use is likely to have minimal impact on vitamin D status,[9](#bjd17992-bib-0009){ref-type="ref"}, [73](#bjd17992-bib-0073){ref-type="ref"}, [74](#bjd17992-bib-0074){ref-type="ref"} even though the action spectra (Fig. [3](#bjd17992-fig-0003){ref-type="fig"}b) for erythema and pre‐vitamin D show considerable UVB overlap.[57](#bjd17992-bib-0057){ref-type="ref"}, [58](#bjd17992-bib-0058){ref-type="ref"} One reason suggested for this is suboptimal sunscreen application, which reduces its efficacy. However, little is known about the minimal UVB dose and exposed BSA requirements to maintain optimal vitamin D status.

Action spectroscopy shows that UVA protection will have no effect on vitamin D synthesis (Figs [3](#bjd17992-fig-0003){ref-type="fig"}b, c), although one *in vitro* study has suggested that UVA2 (315--340 nm) may cause vitamin D degradation,[75](#bjd17992-bib-0075){ref-type="ref"} in which case UVA protection may be beneficial for vitamin D production.

Laboratory and modelling studies have shown that serum 25(OH)D can be increased with repeated suberythemal UVR exposure;[76](#bjd17992-bib-0076){ref-type="ref"}, [77](#bjd17992-bib-0077){ref-type="ref"}, [78](#bjd17992-bib-0078){ref-type="ref"} such doses can be as low as four exposures of 0·375 SED over 24% BSA.[79](#bjd17992-bib-0079){ref-type="ref"} A study of Polish children, who did apply sunscreen, on holiday by the Baltic Sea showed that daily borderline erythemal exposure results in a highly significant increase of serum 25(OH)D~3~.[80](#bjd17992-bib-0080){ref-type="ref"} These studies suggest that vitamin D synthesis occurs with low UVR doses and therefore sufficient UVR may be transmitted through a sunscreen for vitamin D synthesis.

### Sunscreen use and vitamin D status in patients with photosensitivity with strict photoprotection {#bjd17992-sec-0018}

Patients with genetic and acquired photosensitivity disorders, and those at risk of and/or with a history of skin cancer are advised to practice strict photoprotection, including sunscreen use. This population is an ideal group to assess the effects of rigorous photoprotection. Table [2](#bjd17992-tbl-0002){ref-type="table"} shows some of these conditions,[81](#bjd17992-bib-0081){ref-type="ref"}, [82](#bjd17992-bib-0082){ref-type="ref"}, [83](#bjd17992-bib-0083){ref-type="ref"}, [84](#bjd17992-bib-0084){ref-type="ref"}, [85](#bjd17992-bib-0085){ref-type="ref"}, [86](#bjd17992-bib-0086){ref-type="ref"}, [87](#bjd17992-bib-0087){ref-type="ref"}, [88](#bjd17992-bib-0088){ref-type="ref"}, [89](#bjd17992-bib-0089){ref-type="ref"}, [90](#bjd17992-bib-0090){ref-type="ref"}, [91](#bjd17992-bib-0091){ref-type="ref"}, [92](#bjd17992-bib-0092){ref-type="ref"}, [93](#bjd17992-bib-0093){ref-type="ref"} in which patients present with low levels of 25(OH)D~3~ except in the study of Ulrich *et al*.,[86](#bjd17992-bib-0086){ref-type="ref"} in which 25(OH)D~3~ was \> 132·5 nmol L^−1^ in 120 organ transplant recipients. However, it is impossible to attribute low serum 25(OH)D~3~ to a given photoprotection strategy because more than one was used. Furthermore, for the most part there were no controls, and supplementation was given or taken in many of the studies. Overall, it is not possible to use these studies for sunscreen guidance for the general population.

###### 

Vitamin D status in patients with photosensitivity under strict photoprotection

+----------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------+----------------------------------------+----------------------------+---------------------------------------+------------------------------------------+---------------------------------------------------------------------------------------------------+
| First author, year                                       | Pathology and patients (*n*)                                                                                                      | Follow‐up                              | Location, latitude         | Vit D intake                          | Photoprotection strategies               | Vit D status/conclusions                                                                          |
+==========================================================+===================================================================================================================================+========================================+============================+=======================================+==========================================+===================================================================================================+
| Sollitto 1997[81](#bjd17992-bib-0081){ref-type="ref"}    | XP, *n* = 8                                                                                                                       | 6 years                                | U.S.A.: all parts          | 7·7 μg daily                          | SPF \> 15 daily                          | Mean 25(OH)D: 44·5 nmol L^−1^                                                                     |
|                                                          |                                                                                                                                   |                                        |                            |                                       |                                          |                                                                                                   |
|                                                          |                                                                                                                                   |                                        |                            |                                       | Clothing, shade‐seeking                  |                                                                                                   |
+----------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------+----------------------------------------+----------------------------+---------------------------------------+------------------------------------------+---------------------------------------------------------------------------------------------------+
| Querings 2004[82](#bjd17992-bib-0082){ref-type="ref"}    | XP, *n* = 3                                                                                                                       | End of winter                          | Germany: Homburg, 49° N    | NA                                    | Not specified                            | Mean 25(OH)D: 23·8 nmol L^−1^                                                                     |
|                                                          |                                                                                                                                   |                                        |                            |                                       |                                          |                                                                                                   |
|                                                          | BCNS, *n* = 1                                                                                                                     |                                        |                            |                                       |                                          |                                                                                                   |
+----------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------+----------------------------------------+----------------------------+---------------------------------------+------------------------------------------+---------------------------------------------------------------------------------------------------+
| Querings 2006[83](#bjd17992-bib-0083){ref-type="ref"}    | Patients with kidney transplant, *n* = 31                                                                                         | End of winter                          | Germany: Homburg, 49° N    | NA                                    | SS + clothing                            | Mean 25(OH)D: 27·3 nmol L^−1^ vs. 50·0 nmol L^−1^ in controls                                     |
|                                                          |                                                                                                                                   |                                        |                            |                                       |                                          |                                                                                                   |
|                                                          | Controls, *n* = 31                                                                                                                |                                        |                            |                                       |                                          |                                                                                                   |
+----------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------+----------------------------------------+----------------------------+---------------------------------------+------------------------------------------+---------------------------------------------------------------------------------------------------+
| Cusack 2008[84](#bjd17992-bib-0084){ref-type="ref"}      | Cutaneous lupus erythematous, *n* = 52                                                                                            | 3 months in summer                     | Ireland: Dublin, 53° N     | 40·4% took minimum 10 μg daily        | 4 groups:                                | 25(OH)D:57·9 nmol L^−1^                                                                           |
|                                                          |                                                                                                                                   |                                        |                            |                                       |                                          |                                                                                                   |
|                                                          | FST I--IV                                                                                                                         |                                        |                            |                                       | SS user                                  | 58·8 nmol L^−1^                                                                                   |
|                                                          |                                                                                                                                   |                                        |                            |                                       |                                          |                                                                                                   |
|                                                          |                                                                                                                                   |                                        |                            |                                       | Shade seeker                             | 73·5 nmol L^−1^                                                                                   |
|                                                          |                                                                                                                                   |                                        |                            |                                       |                                          |                                                                                                   |
|                                                          |                                                                                                                                   |                                        |                            |                                       | Non‐SS user                              | 81·8 nmol L^−1^                                                                                   |
|                                                          |                                                                                                                                   |                                        |                            |                                       |                                          |                                                                                                   |
|                                                          |                                                                                                                                   |                                        |                            |                                       | Non‐shade seeker                         |                                                                                                   |
+----------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------+----------------------------------------+----------------------------+---------------------------------------+------------------------------------------+---------------------------------------------------------------------------------------------------+
| Holme 2008[85](#bjd17992-bib-0085){ref-type="ref"}       | Erythropoietic protoporphyria, *n* = 201                                                                                          | 7 months, January to July              | U.K.: 51--57·5° N          | 3 took fish liver oil daily           | 80% shade‐seeking 68% used SS when sunny | 25(OH)D: 63% \< 50 nmol L^−1^ 17% \< 25 nmol L^−1^                                                |
+----------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------+----------------------------------------+----------------------------+---------------------------------------+------------------------------------------+---------------------------------------------------------------------------------------------------+
| Ulrich 2009[86](#bjd17992-bib-0086){ref-type="ref"}      | Organ transplant recipients                                                                                                       | 2 years                                | Germany: Berlin, 53° N     | NA                                    | SPF 50^+^, 2 mg cm^−2^                   | 25(OH)D: lower in SS users (132·5 vs. 150·0 nmol L^−1^). Note: these values are very high         |
|                                                          |                                                                                                                                   |                                        |                            |                                       |                                          |                                                                                                   |
|                                                          | Applied SS, *n* = 60                                                                                                              |                                        |                            |                                       |                                          |                                                                                                   |
|                                                          |                                                                                                                                   |                                        |                            |                                       |                                          |                                                                                                   |
|                                                          | No SS, *n* = 60FST II‐III                                                                                                         |                                        |                            |                                       |                                          |                                                                                                   |
+----------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------+----------------------------------------+----------------------------+---------------------------------------+------------------------------------------+---------------------------------------------------------------------------------------------------+
| DeLong 2010[87](#bjd17992-bib-0087){ref-type="ref"}      | Skin cancer patients *n* = 143 FST I‐II, 12 FST IV‐VI, *n* = 144FST I‐IV                                                          | 2 years (September to December period) | U.S.A.: Atlanta, GA, 34° N | 94% \< 10 μg daily from diet          | Adherent or no sun protection            | Mean 25(OH)D:                                                                                     |
|                                                          |                                                                                                                                   |                                        |                            |                                       |                                          |                                                                                                   |
|                                                          |                                                                                                                                   |                                        |                            | 60% taking supplements                |                                          | Adherent: 70 nmol L^−1^ (18% \< 50 nmol L^−1^), Nonadherent: 73 nmol L^−1^ (16% \< 50 nmol L^−1^) |
+----------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------+----------------------------------------+----------------------------+---------------------------------------+------------------------------------------+---------------------------------------------------------------------------------------------------+
| Hoesl 2010[88](#bjd17992-bib-0088){ref-type="ref"}       | XP, *n* = 15                                                                                                                      | NA                                     | Germany: Tubignen, 49° N   | NA                                    | Sun protection                           | Mean 25(OH)D: 27 nmol L^−1^                                                                       |
+----------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------+----------------------------------------+----------------------------+---------------------------------------+------------------------------------------+---------------------------------------------------------------------------------------------------+
| Tang 2010[89](#bjd17992-bib-0089){ref-type="ref"}        | BCNS, *n* = 41                                                                                                                    | 2 years                                | U.S.A.: all parts          | 34% daily multivitamin                | 80% used daily SPF \> 15 daily           | 25(OH)D: 56% with \< 50 nmol L^−1^ compared with 18% controls                                     |
|                                                          |                                                                                                                                   |                                        |                            |                                       |                                          |                                                                                                   |
|                                                          | FST I--III                                                                                                                        |                                        |                            |                                       |                                          |                                                                                                   |
|                                                          |                                                                                                                                   |                                        |                            |                                       |                                          |                                                                                                   |
|                                                          | NHANES controls, *n* = 360                                                                                                        |                                        |                            |                                       |                                          |                                                                                                   |
+----------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------+----------------------------------------+----------------------------+---------------------------------------+------------------------------------------+---------------------------------------------------------------------------------------------------+
| Reid 2012[90](#bjd17992-bib-0090){ref-type="ref"}        | Patients with photosensitivity, *n* = 165 (of which *n* = 35 with strict photoprotection) *n* = 143 &!\#6;FST I‐III, 12 FST IV‐VI | 1 year                                 | Scotland: Dundee, 56° N    | Supplements used by 14 patients       | None, sensible, strict                   | Mean 25(OH)D:                                                                                     |
|                                                          |                                                                                                                                   |                                        |                            |                                       |                                          |                                                                                                   |
|                                                          |                                                                                                                                   |                                        |                            |                                       |                                          | 41·9 nmol L^−1^                                                                                   |
|                                                          |                                                                                                                                   |                                        |                            |                                       |                                          |                                                                                                   |
|                                                          |                                                                                                                                   |                                        |                            |                                       |                                          | 40% with \< 50 nmol L^−1^                                                                         |
|                                                          |                                                                                                                                   |                                        |                            |                                       |                                          |                                                                                                   |
|                                                          |                                                                                                                                   |                                        |                            |                                       |                                          | 25% with \< 25 nmol L^−1^                                                                         |
|                                                          |                                                                                                                                   |                                        |                            |                                       |                                          |                                                                                                   |
|                                                          |                                                                                                                                   |                                        |                            |                                       |                                          | Supplementation associated with significantly higher 25(OH)D (57·5 vs. 39·5 nmol L^−1^)           |
|                                                          |                                                                                                                                   |                                        |                            |                                       |                                          |                                                                                                   |
|                                                          |                                                                                                                                   |                                        |                            |                                       |                                          | Strict vs. sensible photoprotection associated with lower 25(OH)D (33·4 vs. 42·1 nmol L^−1^)      |
+----------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------+----------------------------------------+----------------------------+---------------------------------------+------------------------------------------+---------------------------------------------------------------------------------------------------+
| Gentzsch 2014[91](#bjd17992-bib-0091){ref-type="ref"}    | Gorlin (incl. multiple BCCs), *n* = 1 (case report)                                                                               | NA                                     | Germany: Freiburg, 48° N   | Supplementation initiated             | SS + clothing and shade‐seeking          | 25(OH)D \< 10 nmol L^−1^                                                                          |
+----------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------+----------------------------------------+----------------------------+---------------------------------------+------------------------------------------+---------------------------------------------------------------------------------------------------+
| Kuwabara 2015[92](#bjd17992-bib-0092){ref-type="ref"}    | XP‐A, *n* = 21Japanese                                                                                                            | 2 days for vit D intake                | Japan: Kobe, 35° N         | Mean dietary intake of 4·1 μg day^−1^ | SPF \> 30 + clothing                     | 25(OH)D: 76% \< 25 nmol L^−1^                                                                     |
+----------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------+----------------------------------------+----------------------------+---------------------------------------+------------------------------------------+---------------------------------------------------------------------------------------------------+
| Bogaczewicz 2016[93](#bjd17992-bib-0093){ref-type="ref"} | SLE: *n* = 104, Controls: *n* = 34FST II‐III                                                                                      | 16 weeks                               | Poland: Lodz, 52° N        | After study                           | SS + clothing and hats                   | Summer 25(OH)D:SLE: median 56·8 nmol L^−1^, Controls: median 73·2 nmol L^−1^                      |
+----------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------+----------------------------------------+----------------------------+---------------------------------------+------------------------------------------+---------------------------------------------------------------------------------------------------+

25(OH)D, 25‐hydroxyvitamin D; BCC, basal cell carcinoma; BCNS, basal cell naevus syndrome; FST, Fitzpatrick skin type; NA, data not available or not applicable; NHANES, National Health and Nutrition Examination Survey; SLE, systemic lupus erythematosus; SPF, sun protection factor; SS, sunscreen; XP, xeroderma pigmentosum, vit, vitamin
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### Sunscreen use and vitamin D3 synthesis in studies using nonsolar ultraviolet radiation from artificial sources {#bjd17992-sec-0019}

Laboratory studies offer an obvious way to study the effects of sunscreens under controlled conditions. Five studies have shown that sunscreen application (0·5--2 mg cm^−2^) inhibited the synthesis of vitamin D (Table [3](#bjd17992-tbl-0003){ref-type="table"}).[94](#bjd17992-bib-0094){ref-type="ref"}, [95](#bjd17992-bib-0095){ref-type="ref"}, [96](#bjd17992-bib-0096){ref-type="ref"}, [97](#bjd17992-bib-0097){ref-type="ref"} However, the sources used were mainly UVB‐rich (Fig. [3](#bjd17992-fig-0003){ref-type="fig"}a), including nonsolar UVB (\< 295 nm), which is very effective at pre‐vitamin D production (Fig. [3](#bjd17992-fig-0003){ref-type="fig"}b). Figure [3](#bjd17992-fig-0003){ref-type="fig"}c shows that such nonsolar wavelengths have a disproportionally large effect, and thus do not reflect environmental reality. Of note, one study showed that 25(OH)D synthesis is dependent on application thickness when 25% of BSA is exposed.[96](#bjd17992-bib-0096){ref-type="ref"} It was recently shown that sunscreens block cutaneous vitamin D~3~ (cholecalciferol) production with only a minimal effect on circulating 25(OH)D after a single narrowband UVB (\~313 nm) exposure.[97](#bjd17992-bib-0097){ref-type="ref"} In general, the UVR dose of these studies is low, e.g. this was 0·8 MED (estimated to be \~3 SED in skin type III volunteers) with SPF 50 at 2 mg cm^−2^ in the study of Libon *et al*.[97](#bjd17992-bib-0097){ref-type="ref"} Taking the SPF at face value means the dose through the sunscreen is 3/50 = 0·06 SED. However, it should be noted that the labelled SPF value is specific to SSR sources used for SPF testing that meet certain spectral specifications. The 'actual SPF' with nonsolar UVB‐rich sources may be considerably higher[98](#bjd17992-bib-0098){ref-type="ref"} than labelled SPF in sunlight. This means that the labelled SPFs are in fact meaningless with nonsolar sources. Overall, when taking photobiological considerations into account, the use of sunscreens with non‐SSR sources cannot provide reliable data on their effect on vitamin D synthesis for public health purposes. The only way to do such studies reliably would be to use SSR as used in SPF testing, or a fluorescent SSR source.[99](#bjd17992-bib-0099){ref-type="ref"} It should be noted that the higher UVB content of SSR than 'typical' terrestrial UVR may also influence results.[100](#bjd17992-bib-0100){ref-type="ref"} Furthermore, the SSR doses given should be environmentally realistic and represent a serious challenge to the sunscreen under test.

###### 

Sunscreen use and vitamin D status in studies using normal human volunteers (FST I‐III) exposed to UVR from artificial sources

+--------------------------------------------------------+--------------------------------+----------------------------------------------------------+--------------------+-----------------------------------------------------------------------------------------------------------------------------+---------+---------------------------------+--------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| First author, year                                     | *In vivo* / *ex vivo*,*n*, age | UVR source                                               | Dose               | Exposed area                                                                                                                | SPF     | Amount of sunscreen             | Time of assessment                                     | Conclusions                                                                                                                                                                                                                                                                  |
+========================================================+================================+==========================================================+====================+=============================================================================================================================+=========+=================================+========================================================+==============================================================================================================================================================================================================================================================================+
| Matsuoka 1987[94](#bjd17992-bib-0094){ref-type="ref"}  | *Ex vivo*                      | SSR                                                      | 1 MED              | 6·2 cm^−2^                                                                                                                  | NA      | 5% (w/v) PABA                   | Pre and post UVR                                       | SS blocked photoisomerization of stratum corneum 7‐DHC                                                                                                                                                                                                                       |
|                                                        |                                |                                                          |                    |                                                                                                                             |         |                                 |                                                        |                                                                                                                                                                                                                                                                              |
|                                                        | (skin from 1 donor)            |                                                          |                    |                                                                                                                             |         |                                 |                                                        |                                                                                                                                                                                                                                                                              |
|                                                        |                                |                                                          |                    |                                                                                                                             |         |                                 |                                                        |                                                                                                                                                                                                                                                                              |
|                                                        | *n* = 3 (SS + UVR)             |                                                          |                    |                                                                                                                             |         |                                 |                                                        |                                                                                                                                                                                                                                                                              |
|                                                        |                                |                                                          |                    |                                                                                                                             |         |                                 |                                                        |                                                                                                                                                                                                                                                                              |
|                                                        | *n* = 3 (vehicle + UVR)        |                                                          |                    |                                                                                                                             |         |                                 |                                                        |                                                                                                                                                                                                                                                                              |
|                                                        |                                |                                                          |                    |                                                                                                                             |         |                                 |                                                        |                                                                                                                                                                                                                                                                              |
|                                                        | *n*= 3 (control)               |                                                          |                    |                                                                                                                             |         |                                 |                                                        |                                                                                                                                                                                                                                                                              |
+--------------------------------------------------------+--------------------------------+----------------------------------------------------------+--------------------+-----------------------------------------------------------------------------------------------------------------------------+---------+---------------------------------+--------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Matsuoka 1987[94](#bjd17992-bib-0094){ref-type="ref"}  | In vivo                        | UVB phototherapy tubes (260--360 nm with peak at 313 nm) | 1 MED              | Whole body                                                                                                                  | SPF 8   | Cannot say with confidence      | 24 h, 2 h prior UVR, 1, 2, 3, 7, 14 days post exposure | Without SS there was a 17‐fold increase in serum vit D peaking at 1 day post UVR. SS totally blocked serum vit D increase                                                                                                                                                    |
|                                                        |                                |                                                          |                    |                                                                                                                             |         |                                 |                                                        |                                                                                                                                                                                                                                                                              |
|                                                        | *n* = 8                        |                                                          |                    |                                                                                                                             |         |                                 |                                                        |                                                                                                                                                                                                                                                                              |
|                                                        |                                |                                                          |                    |                                                                                                                             |         |                                 |                                                        |                                                                                                                                                                                                                                                                              |
|                                                        | (SS, n = 4; placebo, *n* = 4)  |                                                          |                    |                                                                                                                             |         |                                 |                                                        |                                                                                                                                                                                                                                                                              |
|                                                        |                                |                                                          |                    |                                                                                                                             |         |                                 |                                                        |                                                                                                                                                                                                                                                                              |
|                                                        | 21--45 years                   |                                                          |                    |                                                                                                                             |         |                                 |                                                        |                                                                                                                                                                                                                                                                              |
+--------------------------------------------------------+--------------------------------+----------------------------------------------------------+--------------------+-----------------------------------------------------------------------------------------------------------------------------+---------+---------------------------------+--------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Matsuoka 1990[95](#bjd17992-bib-0095){ref-type="ref"}  | In vivo                        | UVB phototherapy tubes (260--360 nm with peak at 313 nm) | Slightly \< 1 MED  | Six groups with different SS application zones:                                                                             | SPF 15  | No data                         | 1 h before and 24 h after exposure                     | In the absence of whole‐body SS there was a \~5‐fold significant increase of serum vit D. Whole‐body SS totally blocked vit D formation. Lack of SS on the legs and trunk allowed significant synthesis. But synthesis not significant when arms and head & neck were spared |
|                                                        |                                |                                                          |                    |                                                                                                                             |         |                                 |                                                        |                                                                                                                                                                                                                                                                              |
|                                                        | *n* = 27                       |                                                          |                    | G1, whole body; G2, except head & neck; G3, except arms; G4, except trunk; G5, except buttocks & legs; G6, whole body no SS |         |                                 |                                                        |                                                                                                                                                                                                                                                                              |
|                                                        |                                |                                                          |                    |                                                                                                                             |         |                                 |                                                        |                                                                                                                                                                                                                                                                              |
|                                                        | 23--32 years                   |                                                          |                    |                                                                                                                             |         |                                 |                                                        |                                                                                                                                                                                                                                                                              |
+--------------------------------------------------------+--------------------------------+----------------------------------------------------------+--------------------+-----------------------------------------------------------------------------------------------------------------------------+---------+---------------------------------+--------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Faurschou 2012[96](#bjd17992-bib-0096){ref-type="ref"} | In vivo                        | UVB phototherapy                                         | 4 × 3 SED          | 25% BSA (upper front and back)                                                                                              | SPF 8   | 0, 0·5, 1·0, 1·5, 2·0 mg cm^−2^ | 3 days after final irradiation                         | Increase of 25(OH)D is dependent on SS application thickness. All increases significantly greater than baseline apart from SS at 2·0 mg cm^−2^                                                                                                                               |
|                                                        |                                |                                                          |                    |                                                                                                                             |         |                                 |                                                        |                                                                                                                                                                                                                                                                              |
|                                                        | *n* = 37                       | tubes (290--360 nm with peak at 320 nm)                  | 2--3 days interval |                                                                                                                             |         |                                 |                                                        |                                                                                                                                                                                                                                                                              |
|                                                        |                                |                                                          |                    |                                                                                                                             |         |                                 |                                                        |                                                                                                                                                                                                                                                                              |
|                                                        | 18--49 years                   |                                                          |                    |                                                                                                                             |         |                                 |                                                        |                                                                                                                                                                                                                                                                              |
+--------------------------------------------------------+--------------------------------+----------------------------------------------------------+--------------------+-----------------------------------------------------------------------------------------------------------------------------+---------+---------------------------------+--------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Libon 2017[97](#bjd17992-bib-0097){ref-type="ref"}     | In vivo                        | Narrowband UVB phototherapy tubes (311--313 nm)          | 0·8 MED            | Different body areas with and without SS (9--96%)                                                                           | SPF 50+ | 2 mg cm^−2^                     | Pre and post UVR up to 5 days                          | SS use decreased serum 25(OH)D by 8--13% and decreased cutaneous vit D by 76--93%                                                                                                                                                                                            |
|                                                        |                                |                                                          |                    |                                                                                                                             |         |                                 |                                                        |                                                                                                                                                                                                                                                                              |
|                                                        | *n* = 72                       |                                                          |                    |                                                                                                                             |         |                                 |                                                        |                                                                                                                                                                                                                                                                              |
|                                                        |                                |                                                          |                    |                                                                                                                             |         |                                 |                                                        |                                                                                                                                                                                                                                                                              |
|                                                        | 19--25 years                   |                                                          |                    |                                                                                                                             |         |                                 |                                                        |                                                                                                                                                                                                                                                                              |
+--------------------------------------------------------+--------------------------------+----------------------------------------------------------+--------------------+-----------------------------------------------------------------------------------------------------------------------------+---------+---------------------------------+--------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+

25(OH)D, 25‐hydroxyvitamin D; 7‐DHC, 7‐dehydrocholesterol; BSA, body surface area; MED, minimal erythema dose; NA, not applicable; PABA, para‐aminobenzoic acid; SED, standard erythema dose; SPF, sun protection factor; SS, sunscreen; SSR, solar simulated radiation; vit D, vitamin D \[not 25(OH)D\], UVR, ultraviolet radiation
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### Sunscreen use for daily and recreational photoprotection and vitamin D status {#bjd17992-sec-0020}

#### Questionnaire‐based studies {#bjd17992-sec-0021}

Table [S2](#bjd17992-sup-0001){ref-type="supplementary-material"} (see Supporting Information) shows that most questionnaire‐based studies report no correlation between sunscreen use and serum 25(OH)D~3~ levels. However, two studies showed a negative correlation and a positive correlation was observed in three studies. The negative correlation, in a Brazilian study, reported that 25(OH)D~3~ was sufficient (73 nmol L^−1^) in the sunscreen group.[101](#bjd17992-bib-0101){ref-type="ref"} Godar *et al*. reported, from a modelling study, that young Americans (≤ 19 years) using sunscreen with SPF \> 15 had insufficient vitamin D~3~ status, and concluded that most American children may not get sufficient solar exposure to meet their minimal vitamin D requirements.[102](#bjd17992-bib-0102){ref-type="ref"} One explanation for the positive correlations, including one large Danish study of 2625 adults and 569 children,[103](#bjd17992-bib-0103){ref-type="ref"} is increased solar exposure without erythema.

Questionnaire‐based studies have obvious limitations including compliance, unknown confounding factors, the use of nonsunscreen photoprotection and recall bias. UVR exposure was based on proxies such as time outdoors.

#### Controlled studies {#bjd17992-sec-0022}

Controlled field studies with real sun exposure are the best way to determine the effect of sunscreen use on vitamin D synthesis. Such studies present ethical considerations when considering control groups because lack of sunscreen use could result in sunburn and increased skin cancer risk. Results of such studies are shown in Table [4](#bjd17992-tbl-0004){ref-type="table"},[41](#bjd17992-bib-0041){ref-type="ref"}, [104](#bjd17992-bib-0104){ref-type="ref"}, [105](#bjd17992-bib-0105){ref-type="ref"}, [106](#bjd17992-bib-0106){ref-type="ref"}, [107](#bjd17992-bib-0107){ref-type="ref"}, [108](#bjd17992-bib-0108){ref-type="ref"}, [109](#bjd17992-bib-0109){ref-type="ref"}, [110](#bjd17992-bib-0110){ref-type="ref"}, [111](#bjd17992-bib-0111){ref-type="ref"} which reports that most studies showed no change in serum 25(OH)D~3~ with sunscreen use,[106](#bjd17992-bib-0106){ref-type="ref"}, [107](#bjd17992-bib-0107){ref-type="ref"}, [108](#bjd17992-bib-0108){ref-type="ref"} but two showed reduction.[104](#bjd17992-bib-0104){ref-type="ref"}, [105](#bjd17992-bib-0105){ref-type="ref"} These studies mostly ignore the most important factors that influence outcome, namely personal UVR exposure, sunscreen application thickness and BSA exposed. Marks *et al*.,[105](#bjd17992-bib-0105){ref-type="ref"} who found no difference between sunscreen and control groups, measured UVR exposure in the last week of a 7‐week study in Australia using polysulphone badge personal dosimeters. The UVR exposures in the sunscreen and control groups were not different, but the last week\'s exposure is unlikely to have been critical for the outcome because serum 25(OH)D~3~ was best predicted in Australian adults by solar exposure 6 weeks prior to measurement.[112](#bjd17992-bib-0112){ref-type="ref"}

###### 

Sunscreen use and vitamin D status/outcomes in real sun exposure (controlled studies) in skin cancer patients and healthy volunteers

+--------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------+---------------------------+-----------------------------------------------+-----------------+----------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| First author, year                                                                                           | Participants: *n* (age)                                                                                                                                                                                                                                                                        | Location, latitude                                      | SPF                       | Assessment period                             | Baseline values | UVR monitored                                | Conclusions                                                                                                                                                                                                                 |
+==============================================================================================================+================================================================================================================================================================================================================================================================================================+=========================================================+===========================+===============================================+=================+==============================================+=============================================================================================================================================================================================================================+
| Matsuoka 1988[104](#bjd17992-bib-0104){ref-type="ref"}                                                       | *n* = 20 (65 ±3 years)                                                                                                                                                                                                                                                                         | U.S.A.: Springfield, IL, 40° N; Philadelphia, PA, 40° N | Not given                 | Summer after                                  | No              | No                                           | 25(OH)D significantly lower (44%) in SS group than controls                                                                                                                                                                 |
|                                                                                                              |                                                                                                                                                                                                                                                                                                |                                                         |                           |                                               |                 |                                              |                                                                                                                                                                                                                             |
|                                                                                                              | Controls: *n* = 20 (58 ± 3 years)                                                                                                                                                                                                                                                              |                                                         |                           | SS use \> 1 year                              |                 |                                              |                                                                                                                                                                                                                             |
+--------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------+---------------------------+-----------------------------------------------+-----------------+----------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Marks 1995[105](#bjd17992-bib-0105){ref-type="ref"}                                                          | *n* = 113 (≥ 40 years)                                                                                                                                                                                                                                                                         | Australia: Maryborough, 37° S                           | SPF 17                    | 7 months (after summer)                       | Yes             | Yes                                          | 25(OH)D not significantly different between groups. SS group had significantly lower 1,25(OH)~2~D but still in the reference range. No difference in UVR exposure between groups                                            |
|                                                                                                              |                                                                                                                                                                                                                                                                                                |                                                         |                           |                                               |                 |                                              |                                                                                                                                                                                                                             |
|                                                                                                              |                                                                                                                                                                                                                                                                                                |                                                         | Controls given base cream | 1,25(OH)~2~D also assessed                    |                 | Dosimeter badges (last week)                 |                                                                                                                                                                                                                             |
+--------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------+---------------------------+-----------------------------------------------+-----------------+----------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Farrerons 1998[106](#bjd17992-bib-0106){ref-type="ref"}                                                      | *n* = 24 (71 ± 8 years)                                                                                                                                                                                                                                                                        | Spain: Barcelona, 41° N                                 | SPF 15                    | 2 years, 4 time points                        | Yes             | No                                           | 25(OH)D significantly lower in SS users at 3 time points. Overall, no other differences[b](#bjd17992-note-0011){ref-type="fn"}                                                                                              |
|                                                                                                              |                                                                                                                                                                                                                                                                                                |                                                         |                           |                                               |                 |                                              |                                                                                                                                                                                                                             |
|                                                                                                              | Controls: *n* = 19 (59 ± 7 years)                                                                                                                                                                                                                                                              |                                                         |                           | 1,25(OH)~2~D, PTH, bone markers also measured |                 | Outdoors ≥ once daily                        |                                                                                                                                                                                                                             |
+--------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------+---------------------------+-----------------------------------------------+-----------------+----------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Farrerons 2001[107](#bjd17992-bib-0107){ref-type="ref"}                                                      | *n* = 10 (74 ± 18 years)[a](#bjd17992-note-0111){ref-type="fn"}                                                                                                                                                                                                                                | Spain: Barcelona, 41° N                                 | SPF 15                    | 2 years                                       | Yes             | No                                           | No significant differences in bone mass between the two groups                                                                                                                                                              |
|                                                                                                              |                                                                                                                                                                                                                                                                                                |                                                         |                           |                                               |                 |                                              |                                                                                                                                                                                                                             |
|                                                                                                              | Controls: *n* = 18 (59 ± 7 years)                                                                                                                                                                                                                                                              |                                                         |                           | Bone mass                                     |                 | Outdoors ≥ once daily                        |                                                                                                                                                                                                                             |
+--------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------+---------------------------+-----------------------------------------------+-----------------+----------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Azizi 2012[108](#bjd17992-bib-0108){ref-type="ref"}                                                          | Outdoor male workers (\~ 40 years)                                                                                                                                                                                                                                                             | Israel, 30--33° N                                       | SPF 42                    | Two successive winters (8 and 20 months)      | No              | Yes                                          | 25(OH)D not significantly different at any time or between any intervention group                                                                                                                                           |
|                                                                                                              |                                                                                                                                                                                                                                                                                                |                                                         |                           |                                               |                 |                                              |                                                                                                                                                                                                                             |
|                                                                                                              | 3 sun protection intervention groups:[c](#bjd17992-note-0012){ref-type="fn"}                                                                                                                                                                                                                   | 3 locations                                             |                           |                                               | (samples lost)  | Ambient                                      |                                                                                                                                                                                                                             |
|                                                                                                              |                                                                                                                                                                                                                                                                                                |                                                         |                           |                                               |                 |                                              |                                                                                                                                                                                                                             |
|                                                                                                              | Complete: health education and training at start of study and at 12 months. SS (SPF 42) given at 12 monthsPartial: health education and training at start of study; SS (SPF 15) given at 12 months (a local protocol deviation)Minimal: end of study only: health education given at 12 months |                                                         |                           |                                               |                 | SED/day                                      |                                                                                                                                                                                                                             |
|                                                                                                              |                                                                                                                                                                                                                                                                                                |                                                         |                           |                                               |                 |                                              |                                                                                                                                                                                                                             |
|                                                                                                              |                                                                                                                                                                                                                                                                                                |                                                         |                           |                                               |                 | 40 ± 10 spring                               |                                                                                                                                                                                                                             |
|                                                                                                              |                                                                                                                                                                                                                                                                                                |                                                         |                           |                                               |                 |                                              |                                                                                                                                                                                                                             |
|                                                                                                              |                                                                                                                                                                                                                                                                                                |                                                         |                           |                                               |                 | 15 ± 4 winter                                |                                                                                                                                                                                                                             |
+--------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------+---------------------------+-----------------------------------------------+-----------------+----------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Jayaratne 2012[110](#bjd17992-bib-0110){ref-type="ref"}                                                      | *n* = 556 (daily sunscreen) vs. *n* = 557 (discretionary use)                                                                                                                                                                                                                                  | Australia: Nambour, 26° S                               | SPF 16                    | End of a 4·5‐year RCT                         | No              | No                                           | 25(OH)D not significantly different in daily vs. discretionary SS use                                                                                                                                                       |
|                                                                                                              |                                                                                                                                                                                                                                                                                                |                                                         |                           |                                               |                 |                                              |                                                                                                                                                                                                                             |
|                                                                                                              | (19--70+ years)                                                                                                                                                                                                                                                                                |                                                         |                           |                                               |                 |                                              |                                                                                                                                                                                                                             |
+--------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------+---------------------------+-----------------------------------------------+-----------------+----------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Narbutt 2019[41](#bjd17992-bib-0041){ref-type="ref"} and Young 2019[111](#bjd17992-bib-0111){ref-type="ref"} | *n* = 79 (34 ± 8 years)                                                                                                                                                                                                                                                                        | Participants: Spain: Tenerife, 28° N                    | SPF 15 (≥ 2 mg cm^−2^)    | 1‐week holiday in March                       | Yes             | Yes                                          | SS SPF 15 (no sunburn) reduced 25(OH)D compared with discretionary use (sunburn) but all increases highly significant. Significantly more 25(OH)D with high UVA‐PF SS. No difference in UVR exposure between holiday groups |
|                                                                                                              |                                                                                                                                                                                                                                                                                                |                                                         |                           |                                               |                 |                                              |                                                                                                                                                                                                                             |
|                                                                                                              |                                                                                                                                                                                                                                                                                                | Controls: Poland: Łódź, 52° N                           | Intervention:             |                                               |                 | Personal electronic dosimeters measuring SED | No change in control group in Poland                                                                                                                                                                                        |
|                                                                                                              |                                                                                                                                                                                                                                                                                                |                                                         |                           |                                               |                 |                                              |                                                                                                                                                                                                                             |
|                                                                                                              |                                                                                                                                                                                                                                                                                                |                                                         | \(i\) High UVA‐PF         |                                               |                 |                                              |                                                                                                                                                                                                                             |
|                                                                                                              |                                                                                                                                                                                                                                                                                                |                                                         |                           |                                               |                 |                                              |                                                                                                                                                                                                                             |
|                                                                                                              |                                                                                                                                                                                                                                                                                                |                                                         | \(ii\) Low UVA‐PF         |                                               |                 |                                              |                                                                                                                                                                                                                             |
|                                                                                                              |                                                                                                                                                                                                                                                                                                |                                                         |                           |                                               |                 |                                              |                                                                                                                                                                                                                             |
|                                                                                                              |                                                                                                                                                                                                                                                                                                |                                                         | Discretionary SS use      |                                               |                 |                                              |                                                                                                                                                                                                                             |
+--------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------+---------------------------+-----------------------------------------------+-----------------+----------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+

1,25(OH)~2~D, 1,25‐dihydroxyvitamin D; 25(OH)D, 25‐hydroxyvitamin D; RCT, randomized control trial; SED, standard erythema dose; SPF, sun protection factor; SS, sunscreen; UVA‐PF, UVA protection factor; UVR, ultraviolet radiation

Paper gives 2 different values for age. This considered more likely.

Significant reduction of bone turnover marker (osteocalcin) in one autumn measurement.

The interventions are described in more detail in Azizi *et al*.,[109](#bjd17992-bib-0109){ref-type="ref"} an earlier paper by the authors relating to the same study. SS included sunglasses and wide‐brimmed hats.
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One factor that has been ignored in all types of study described above, except for the study of Faurschou *et al*.,[96](#bjd17992-bib-0096){ref-type="ref"} is the effect of baseline 25(OH)D~3~ on the response to UVR. The lower the baseline, the greater the response to UVR[113](#bjd17992-bib-0113){ref-type="ref"} and this must be considered in the statistical analyses. A similar observation has been made in vitamin D supplementation studies.[114](#bjd17992-bib-0114){ref-type="ref"}

A holiday study in Tenerife (Canary Islands) during a week of very high UVI was designed to take the above factors into account, including a discretionary sunscreen‐use control group. This showed that intervention with optimal SPF 15 sunscreen use (≥ 2 mg cm^−2^), which inhibited erythema,[41](#bjd17992-bib-0041){ref-type="ref"} still enabled very considerable vitamin D production[111](#bjd17992-bib-0111){ref-type="ref"} compared with the discretionary sunscreen‐use group that had sunburn. A comparison of high vs. low UVA‐PF showed greater vitamin D synthesis with the former. Thus, optimal UVA+B protection does not compromise vitamin D increase during recreational exposure. It was estimated that the daily UVR dose through the sunscreen was 0·4 SED, which is equivalent to 0·1 MED in a fair‐skinned person.[41](#bjd17992-bib-0041){ref-type="ref"} Thus, the UVB doses needed for the biosynthesis of vitamin D~3~ are indeed very low. Overall, this study shows that it is possible to have the benefits or solar exposure while minimizing the risks.

In conclusion, effective sunscreens must attenuate UVB to prevent erythema. In theory, this should inhibit vitamin D~3~ biosynthesis. However, the doses of UVB necessary are low (i.e. substantially suberythemal) so that typical sunscreen use does not lead to vitamin D insufficiency in practice in healthy people. Indeed, even optimal sunscreen use allows good vitamin D synthesis under high UVI conditions. Better UVA protection for a given SPF results in a *de facto* reduction of UVB protection. UVA protection will have no impact on vitamin D synthesis (see Fig. [3](#bjd17992-fig-0003){ref-type="fig"}b), and indeed may prevent photodegradation. Increased UVB for a given SPF should in theory and in practice result in better vitamin D synthesis. Studies done to date have been with lighter‐skinned individuals, and conclusions may not apply to those with darker skin types IV--VI who use sunscreens. In such cases, oral supplementation may be advisable.

Summary {#bjd17992-sec-0023}
=======

Cutaneous vitamin D~3~ synthesis is initiated by terrestrial‐range UVB and can be achieved with suberythemal exposures to a relatively small BSA. Daily sunscreen use, for nonintentional solar exposure, is mainly based on products with low SPF and high UVA‐PF. This is unlikely to impact on vitamin D production. In fact, most studies published to date have shown no association between sunscreen use and vitamin D deficiency, even with regular use of SPF \> 15. Some studies have even reported a positive association between sunscreen use and 25(OH)D~3~, suggesting that their use may have increased sun exposure. Indeed, time spent outdoors and BSA exposed to sun have been positively correlated with vitamin D status. Overall, other photoprotection behaviours (such as seeking shade, wearing protective clothing and long sleeves) may have more impact on vitamin D status than sunscreen use. The recommendations of the panel for daily and recreational photoprotection, as well as the need for vitamin D screening and supplementation, are summarized in Table [5](#bjd17992-tbl-0005){ref-type="table"}.

###### 

General recommendations

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Key messages** The concentration of serum 25(OH)D is a good indicator of vitamin D status. Target serum 25(OH)D should be at least 50 nmol L^−1^ (20 ng mL^−1^).Vitamin D status is modulated by many intrinsic and extrinsic factors including genetic polymorphisms, skin type (pigmentation), age, health, sun exposure behaviour, season, latitude, clothing and nutrition.Routine 25(OH)D screening is not recommended for healthy children and adults, nor is systemic oral vitamin D supplementation. However, it should be considered for people with deeply pigmented skins, those wearing clothing that covers most of the body, especially during pregnancy, and the elderly, or persons in institutions.Daily photoprotection is recommended for all skin phototypes, subject to local weather conditions and activities. This includes seeking shade, wearing hats and clothing, using sunglasses and broad‐spectrum sunscreen use on exposed skin. These strategies will help prevent sunburn, skin cancer and photoageing.SPF should also be adapted to lifestyle (clothing, outdoor activity, diet). High UVA‐PF is advised in all cases. The panel recommends:☐A daily use of low SPF protection (i.e. SPF 15) with UVA‐PF protection in temperate climates with low UVB in wintertime to inhibit photoageing.☐SPF 30 in countries/locations with intense UVB radiation (lower latitudes, high altitudes) irrespective of season.☐High SPF and UVA‐PF for recreational activities under intense solar exposure along with clothing and the use of shade.Sunscreen use for daily and recreational photoprotection need not compromise skin vitamin D synthesis, even when applied under optimal conditions. Increasing the UVA‐PF for a given SPF improves vitamin D~3~ production.Patients with genetic or acquired photosensitivity disorders require strict photoprotection. Also at risk are patients with a history of skin cancer and organ transplant recipients and those with malabsorption syndromes. Daily SPF 50+ with high UVA protection is strongly recommended for all these patients along with wearing protective clothing and seeking shade. This makes them prone to vitamin D deficiency and supplementation and screening is therefore advised for this population.
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

25(OH)D, 25‐hydroxyvitamin D; SPF, sun protection factor; UVA‐PF, ultraviolet A protection factor
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Supporting information
======================

###### 

**Appendix S1** Intrinsic and extrinsic factors that determine serum 25(OH)D.

**Appendix S2** What is optimal vitamin D status and the best method to determine it? Public health perspectives.

**Table S1** Indications for 25(OH)D screening.

**Table S2** Sunscreen use and vitamin D status in real sun exposure (questionnaire‐based and modelled studies).

###### 

Click here for additional data file.
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